← Back to Home

Moving PARP Inhibitors to the Treatment Front Line: Talzenna Plus Xtandi Granted FDA Priority Review

A 599-patient Phase 3 trial showed that the two-drug treatment reduced the risk of radiographic progression or death by 52%; the FDA is expected to decide in the fourth quarter of 2026 whether these results can move precision treatment earlier in the course of metastatic prostate cancer.

By SURL BioNews

For patients with metastatic prostate cancer harboring homologous recombination repair (HRR) gene alterations, precision treatment options currently tend to become more widely available only after the disease reaches the castration-resistant stage. The U.S. Food and Drug Administration (FDA) is now conducting a priority review of an application to expand the indication for Talzenna plus Xtandi, potentially moving the combination earlier to the stage when the disease remains sensitive to hormone therapy and changing the timing of treatment intervention.

Pfizer is seeking an indication for HRR-altered metastatic castration-sensitive prostate cancer. Talzenna (talazoparib) is a PARP inhibitor that impedes the repair of DNA damage, making it more difficult for cancer cells with pre-existing repair defects to survive; Xtandi (enzalutamide) inhibits androgen receptor signaling. Used together, they are intended to simultaneously cut off the tumor’s hormone-driven growth and its alternative DNA repair pathway.

The application is based primarily on the Phase 3 TALAPRO-3 trial. ClinicalTrials.gov registration data show that this is a randomized, double-blind study involving 599 patients with defects in DNA damage repair genes, comparing talazoparib plus enzalutamide with placebo plus enzalutamide. The trial is sponsored by Pfizer in collaboration with Astellas, and the primary analysis was completed in February 2026.

According to results released by Pfizer and reported by Reuters, the two-drug group had a 52% lower risk of radiographic disease progression or death than the control group. The magnitude of this reduction supports expedited regulatory review, but the summary currently available does not provide data on overall survival, outcomes in different HRR gene subgroups, quality of life, or complete adverse-event findings. It is therefore not yet sufficient to determine whether the delay seen on imaging can translate into longer survival or better daily functioning.

Priority review does not mean approval; it shortens the FDA’s target review period from the standard approximately 10 months to approximately 6 months. The FDA is expected to complete its decision in the fourth quarter of 2026, and the same indication is also under review by the European Medicines Agency. If approved, genetic testing will more directly influence whether patients receive an added PARP inhibitor early in metastatic disease, while also bringing the trade-offs among efficacy gains, additional toxicity, and treatment burden into clinical decision-making at an earlier stage.

The study is still listed as ongoing and no longer recruiting, with overall trial completion expected in August 2027. This regulatory development therefore confirms first and foremost that the application has entered expedited review, not that every question about efficacy and safety has been answered. Full data, long-term follow-up, and whether populations with different gene alterations benefit equally will be important evidence in assessing whether this combination can become a front-line treatment.

References

  1. Pfizer
  2. Reuters
  3. ClinicalTrials.gov